The global actinic keratosis treatment market is anticipated to exhibit a CAGR of 4.7% during the forecast period. The rising advancement in actinic keratosis treatment options is anticipated to drive the growth of the global market. Cumulative sun exposure is the single most important cause of actinic keratosis. Lesion-specific therapy, field therapy, and PDT are the major therapies that are being used in the treatment of actinic keratosis. Cryotherapy using liquid nitrogen is a commonly used therapy for actinic keratosis treatment. This method destroys the keratinocytes through freezing, while mostly preserving important dermal structures such as blood vessels, nerves, and collagen due to their higher resistance to cold.
Field therapy involves the treatment of an entire face (field) that is marked by the presence of visible actinic keratosis. It is increasingly accepted as another modality of treatment as it treats visible actinic keratosis and expanded clones of dysplastic cells at the subclinical and cellular level in that region of UV damaged skin as well. Good tolerability and efficacy, and the excellent cosmetic outcome are the major benefits of field therapy. PDT therapy involves the application of a pre-photosensitizer to the area of the skin being treated. The phototoxic reactions can cause adverse events such as erythema, stinging, itching, oedema, and exudation. This factor may restrain the adoption of this therapy for the treatment of actinic keratosis across the globe.
To Request a Sample of our Report on Actinic Keratosis Treatment Market: https://www.omrglobal.com/request-sample/actinic-keratosis-treatment-market
Market Coverage
- The market number available for – 2022-2030
- Base year- 2022
- Forecast period- 2023-2030
- Segment Covered- By Treatment Type, End-User
- Regions Covered- North America, Europe, Asia-Pacific, Rest of the World
- Competitive Landscape- Bausch Health Companies, Inc., Biofrontera AG, BioLineRx, Ltd., Cipher Pharmaceuticals, Inc., Galderma S.A., Hill Dermaceuticals, Inc., LEO Pharma A/S, Valeant Pharmaceuticals Inc., and so on
Actinic Keratosis Treatment Market Report Segment
By Type
- Medication
- Therapy
- Other
By End-User
- Hospitals & Oncology Centers
- Dermatology Clinics
A full Report of Actinic Keratosis Treatment Market is Available at: https://www.omrglobal.com/industry-reports/actinic-keratosis-treatment-market
Actinic Keratosis Treatment Market Report Segment
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Company Profiles
- 3M Co.
- Alma Lasers, Inc.
- Almirall, S.A.
- Bausch Health Companies Inc.
- Biofrontera AG
- BioLineRx, Ltd.
- Cipher Pharmaceuticals, Inc.
- Galderma S.A.
- Hill Dermaceuticals, Inc.
- LEO Pharma A/S
- Mylan N.V.
- Stanford Chemicals Company
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industries, Ltd.
- Valeant Pharmaceuticals, Inc.
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offer Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
